2020/12/1
Having been awarded the 12th National Innovation Award in 2015 and the Excelsior Award in 2019, TaiRx’s anti-cancer drug CVM-1118 won the renewal of Excelsior Award in 2020 to praise and recognize CVM-1118’s continuing innovations and advancements in R&D. CVM-1118 (Foslinanib), currently at the stage of Phase II clinical trials, is a potential first-in-class drug for anti-tumor growth and metastasis via strong inhibition on vasculogenic mimicry pathway.
Dr. Yen-Ling Chen, Senior Manager, received the Award on behalf of TaiRx at the 17th National Innovation Award Ceremony (Photo from Research Center for Biotechnology and Medicine Policy)